OBJECTIVE: To test the hypothesis that the hepatic secretion of very-low-density lipoprotein (VLDL) apolipoprotein B-100 (apoB) is increased in men with visceral obesity and to examine whether the oversecretion of this apolipoprotein is related to insulin resistance and increased hepatic availability of lipid substrates. SUBJECTS: 16 obese men (body mass index (BMI) b 30 kg/m 2 , waist circumference b 100 cm) and 16 non-obese, age matched men, were studied. MEASUREMENTS: The hepatic secretion of VLDL apoB was measured using a primed (1 mg/kg), constant (1 mg/kg/ h), intravenous infusion of 1-[
Introduction
There are various topographical forms of obesity of which the most clinically important is visceral obesity, typically seen in overweight men. 1 Increasing levels of abdominal visceral adipose tissue are closely linked with insulin resistance, 2 dyslipidaemia 1 and hypertension. 3 Although the mechanisms whereby visceral obesity results in dyslipidaemia have not been fully established, it has been suggested that it is associated with an increased hepatic secretion of very-low-density lipoprotein (VLDL) apolipoprotein B-100 (apoB), 4 possibly resulting from the effects of insulin resistance 5 and lipogenic properties of visceral adipose tissue. 6 ApoB is a constitutively expressed glycoprotein that is synthesized exclusively in hepatocytes and secreted into plasma chie¯y as VLDL. 7 The hepatic secretion of VLDL apoB is an independent risk factor for coronary heart disease. 8 Although the precise regulation of the metabolism of VLDL apoB has not been fully established, it has been suggested that the secretion is controlled by the supply of cholesterol substrate to the liver. 9, 10 Support for this notion is based on in vitro experiments 11 and observations in human subjects. 12 However, the opposite conclusion has been reported by Wu et al 13 who demonstrated that in HepG2 cells, the principal regulator of VLDL apoB secretion is triglyceride synthesis. In vitro studies suggest that the hepatic secretion of VLDL apoB is dependent on the availability of free fatty acids that determine the synthetic rates of both cholesterol esters and triglycerides. 11, 13 Both in vitro 14, 15 and in vivo 16, 17 studies have shown that insulin inhibits the hepatic secretion of VLDL apoB. In vivo data have also shown that enhanced cholesterol synthesis is a feature of insulin resistance 18 and that acute hyperinsulinaemia diminishes the rate of cholesterogenesis as measured by the plasma concentration of mevalonic acid. 19 In visceral obesity, insulin resistance may increase de novo cholesterol synthesis, thereby resulting in an increased rate of hepatic secretion of VLDL apoB. 20 This effect may be compounded by increased supply of free fatty acids to the liver and triacylglycerol availability.
Using a stable isotope method, we have reported 4 a direct correlation between fat mass and the hepatic secretion of VLDL apoB in obese subjects. However, in our previous study, the number of subjects studied was small, males and females were included and not all the obese subjects had visceral obesity. Further support for the notion that apoB secretion is increased in insulin resistant states such as visceral obesity, is derived from our previous demonstration that the acute effect of insulin has a direct inhibitory effect on apoB secretion by the liver in normolipidaemic subjects and patients with non-insulin dependent diabetes. 17, 18 Previous radiokinetic studies investigating the secretion of this apolipoprotein did not measure visceral obesity 21±25 and again only a small number of subjects were studied. The advantages of employing stable isotopes as opposed to radioactive tracers to study apoB metabolism have been well documented. 26 In the present study, our objective was to employ a stable isotope technique and a reasonable number of well characterised volunteers to test the hypothesis that the hepatic secretion of VLDL apoB is increased in visceral obesity, and that oversecretion of this apolipoprotein may be a consequence of insulin resistance and an increased hepatic availability of cholesterol and other lipid substrates.
Subjects and methods

Subjects
We studied 16 men with visceral obesity and 16 age and gender matched, non-obese (body mass index (BMI) 20±28 kgam 2 ) subjects. Visceral obesity was de®ned as a BMI b 30 kgam 2 , waist-to-hip ratio (WHR) b1.0 and waist circumference b100 cm. The subjects with visceral obesity were randomly selected from 78 free living, apparently healthy men being screened for obesity studies and who met the criteria for having visceral obesity. The subjects were recruited from the community via newspaper advertisement.
None of the subjects had diabetes mellitus, proteinuria, hypothyroidism, abnormal liver enzymes or a history of alcohol abuse. None reported a family history of hyperlipidaemia or premature coronary artery disease or were taking medication known to affect lipid metabolism. All subjects provided written consent and the study was approved by the Ethics Committee of the Royal Perth Hospital.
Clinical protocol
Weight and height were measured without shoes and in light clothing. Waist circumference (cm) was measured at the point midway between the costal margin and iliac crest in the mid-axillary line. Hip circumference (cm) was measured at the widest point around the greater trochanter. BMI (weight in kg divided by height 2 in metres) and the WHR were calculated. Body composition was estimated by a bioelectrical impedance method using a Holtain Body Composition Analyser (Holtain Ltd, Dyfed, UK). Measurements of fat mass (FM) and fat free mass (FFM) were recorded.
All subjects were admitted to the metabolic ward after at least a 14 h fast. They were studied in a semirecumbent position and allowed water only. Venous blood was collected into sodium edetic acid (EDTA, 0.1 M) for measurements of plasma concentrations of total cholesterol, triglycerides, High-density lipoprotein (HDL) cholesterol, mevalonate and assessment of apolipoprotein E (apoE) genotype. 1-[ 13 C]-leucine (99.5% enrichment) (Tracer Technologies, MA, USA) was administered by a primed (1 mg/kg), constant (1 mgakgah) intravenous infusion (10 h duration) via a te¯on cannula placed into a super®cial vein of the left antecubital fossa. Venous blood was collected via a cannula from the contralateral arm to measure isotopic enrichment of apoB. During the study, plasma was obtained at 09.00 h for assay of plasma mevalonic acid and lathosterol concentration.
Dietary methods
All subjects were consuming ad libitum diets. Weight variation in the four weeks prior to the commencement of the study was`3%. Dietary intake was assessed for energy and major nutrients using at least two 24 h dietary diaries which were subsequently analysed by a dietitian using DIET 4 Nutrient Calculation Software (Xyris Software, Queensland, Australia).
Laboratory methods
The laboratory methods for the study have been fully described elsewhere 27 and are further summarised below.
Isolation and measurement of isotopic enrichment of VLDL apoB. A 3 ml aliquot of plasma was overlayed with 1.6 ml sodium chloride solution (d 1.006 kgaL). The samples were ultracentrifuged for 16 hours at 147 000 g (Centrikon T-1190, Kontron Instruments, Milan, Italy) and the apoB precipitated by the isopropanol method. 28 This technique is highly speci®c for isolating apoB-100 and was positively VLDL apoB secretion in men with visceral obesity FM Riches et al associated with VLDL apoB concentration as measured by immunoturbidimetry (r 0.89, P`0.001, n 27) (Riches FM et al, unpublished observation, 1996). The precipitate was then delipidated with ether ethanol (1 : 3 vav), dried and hydrolysed by the addition of 2 ml of 6 M hydrochloric acid. After the samples were hydrolysed for 24 h at 105 C, 50% acetic acid was added. The amino acids were extracted by cation-exchange chromatography and eluted using 2 ml of 3 M ammonia. The samples were derivatised using N-methyl-N-(tert-butyldimethylsilyl)-tri¯uoroacetamide in acetonitrile and reconstituted in decane for Gas ChromatographyMass Spectrometry (GCMS) analysis (Hewlett Packard 5890, Wilmington, USA). Isotopic enrichment was determined by selected ion monitoring of derivitized samples at a mass to charge ratio (maz) of 303 and 302 and using electron-impact ionization. Leucine enrichment was calculated using the formula 29 :
where R t is the Quanti®cation of VLDL apoB and other analytes. In each individual study from the onset of 1-[ 13 C]-leucine infusion, samples were combined to yield three pooled VLDL samples per study. A modi®ed Lowry method 30 was used to determine the VLDL apoB concentration in each pooled sample. The interassay coef®cient of variation (CV) was`4.5%.
Plasma total cholesterol, triglyceride and HDL concentrations were determined enzymatically using a Cobas Mira Analyser (Roche Diagnostics, Basle, Switzerland). In subjects with a triglyceride concentration`4.5 mmolaL, low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald equation. One subject had a triglyceride concentration b 4.5 mmolaL. In this instance, LDL cholesterol concentration was calculated as: LDL cholesterol total cholesterol7(VLDL cholesterol HDL cholesterol), cholesterol concentration being assayed directly in the VLDL fraction isolated by ultracentrigufation. Genomic DNA was extracted by the standard Triton X-100 procedure and the genotype for apoE determined as described by Hixson and Vernier. 31 Plasma insulin was measured by an immuno enzymometric assay using a Tosoh Automated Immunoassay analyser (Tosoh Corporation, Tokyo, Japan); CV`7.0%. Plasma glucose concentration was measured by an enzymatic hexokinase reaction method using a Technicon Axon analyser (Bayer Diagnostics, New York, USA); CV`3.1%. An enzymatic colorimetric assay and Roche Cobas Mira analyser (Roche Diagnostics, Basle, Switzerland) was used to determine the concentration of plasma free fatty acids; CV`3.0%. Plasma mevalonic acid concentration was measured by capillary gas chromatography-electron capture mass spectrometry 32 ; the interassay CV was 5.9%. Plasma lathosterol concentration was assayed as described by Mori et al 33 using a GCMS (Hewlett Packard 5890, Wilmington, USA); interassay CV 6.0%. The plasma lathosterol : cholesterol ratio was calculated.
Calculation of VLDL apoB turnover rate.
It has been proposed that Z(t) is the preferred variable to analyze tracer kinetics. 29 This was derived from enrichment data according to the equation:
where E(t) is the isotopic enrichment of VLDL apoB at time t and E(I) is the isotopic enrichment of the infusate. The fractional secretion rate of VLDL apoB (poolsad), equivalent to the fractional catabolic rate (FCR) at steady state concentration was determined using a multicompartmental model. SAAM-II (SAAM Institute, University of Washington, Seattle, USA) was used to ®t the model to the tracer data. The model consisted of three compartments as described below:
Compartment 1 is a plasma leucine compartment in which 13 C enrichment of plasma leucine was employed as the forcing function for the precursor pool in the liver; Compartment 2 is an adjustable intrahepatic delay compartment for the assembly of VLDL apoB and secretion into the blood and compartment 3 is a plasma compartment for VLDL apoB secreted by the liver. In interpreting these stable isotope studies, the model is based on the following assumptions: (i) the subjects were in a metabolic steady state, (ii) the plasma leucine is the source of the leucine that is incorporated into apoB, (iii) all apoB enters the plasma via VLDL particles and (iv) the time required for each subject to synthesize and secrete VLDL apoB ranges between 10±50 min. 34 The absolute secretion rate (ASR) of VLDL apoB was calculated as the product of FSR and pool size. Pool size was determined as the product of plasma volume and the mean plasma VLDL apoB concentration. The plasma volume was calculated by multiplying body weight by 0.045. 35 In the obese subjects, the plasma volume was modi®ed by multiplying by a correction factor to take into consideration the decrease in relative plasma volume associated with an increase in body weight. 36 The correction factor was calculated using the formula:
VLDL apoB secretion in men with visceral obesity FM Riches et al orretion ftor 7reltive ody weight À 310 À215 The corrected plasma volume in the obese subjects was positively correlated with plasma volume as measured at the mid-point of each study by standard isotopic dilution technique (r 0.74, P 0.001, n 16) (Riches FM et al, unpublished observation, 1996).
Statistical methods
An unpaired t-test was used to compare group characteristics. Skewed variables (plasma concentrations of triglyceride and lathosterol) were examined after log. transformation. As in our previous study 4 we expressed VLDL apoB ASR as mgakg FFMad. Associations between VLDL apoB ASR (mgakg FFMad) and other variables were examined using simple and multiple linear regression methods. The apoE genotype was described as a binary variable (1 E2aE3, 2 E3aE3, 3 E4aE3, 4 E4aE4) in regression analyses.
Results Table 1 shows the clinical characteristics of the subjects studied. The obese subjects had a signi®-cantly higher body weight (P`0.001), BMI (P`0.001), waist circumference (P`0.001), WHR (P`0.001), FM (P`0.001) and FFM (P 0.004). Table 2 shows the daily energy and nutrient intake (mean AE s.d.) of the obese and control subjects. Dietary fat (grams and % of total energy) and cholesterol intake was signi®cantly higher in the obese subjects (P`0.031). Carbohydrate intake (% of total energy) was signi®cantly higher in the control subjects. There were no other signi®cant differences in either energy or nutrient intake between the groups. Table 3 shows the plasma lipid and lipoprotein in the non-obese and obese subjects. Plasma concentrations of total cholesterol, triglycerides, VLDL cholesterol and VLDL triglycerides were signi®cantly higher in the obese subjects compared with the controls (P`0.05). Plasma HDL cholesterol concentration was signi®cantly lower (P 0.005) in obese than control subjects. Of the control subjects, eight were apolipoprotein E3aE3 homozygotes, six were E4aE3 heterozygotes and two were E2aE3 heterozygotes. One obese subject was E4aE4 homozygote, nine were E3aE3 homozygotes, four were E4aE3 heterozygotes and two were E2aE3 heterzygotes. The frequency distributions of apoE genotypes were not signi®cantly different between the groups. Table 4 shows the plasma concentrations of insulin, glucose, free fatty acids and cholesterol precursors in the subjects studied. Plasma insulin and glucose concentrations were signi®cantly higher (P 0.02) in the obese subjects compared with controls. Plasma free fatty acid concentrations did not differ signi®cantly between the groups. Plasma mevalonic acid and lathosterol concentrations and the lathosterol : cholesterol ratio were signi®cantly higher (P`0.001) in the obese group. Figure 1 shows the isotopic enrichment curve (mean AE s.e.m.) for the plasma leucine and VLDL apoB in the 16 non-obese ( Figure 1A ) and 16 obese subjects ( Figure 1B ) during the infusion of 1-[ 13 C]-leucine. In all subjects, steady state plasma leucine enrichment was attained within 30 min of infusion. Steady state isotopic enrichment in VLDL apoB was reached after 6 h in the controls but not in the obese subjects. Table 5 describes the metabolism of VLDL apoB in the subjects studied. VLDL apoB concentration (mgaL), pool size (mg), and the hepatic secretion of VLDL apoB (expressed as mgad and mgakg FFMad) were signi®cantly higher (P 0.02) in the obese than the non-obese subjects. The mean FCR was higher in the non-obese vs the obese subjects, the difference approaching signi®cance at the 5% level.
In the controls, there was a signi®cant correlation between the hepatic secretion of VLDL apoB (mgakgFFMad) and the WHR (r 0.62, P 0.01). In the obese subjects, the hepatic secretion of VLDL apoB (mgakg FFMad) was signi®cantly correlated with triglyceride concentration (r 0.58, P 0.020), VLDL cholesterol concentration (r 0.58, P 0.023), VLDL triglyceride concentration (r 0.57, P 0.028) and percentage fat intake (r 0.64, P 0.008). There was no association between plasma glucose concentration at 120 min after a 75 g glucose load and the hepatic secretion of VLDL apoB in the obese subjects (data not shown). There were no other signi®cant correlations between the hepatic secretion of VLDL apoB and the physical, biochemical or dietary variables measured in either group.
After pooling data from both study groups, there was a signi®cant association between VLDL apoB secretion rate (mgakg FFMad) and WHR (r 0.58, P`0.001) waist circumference (r 0.50, P 0.004), BMI (r 0.46, P 0.008) and with the plasma concentrations of triglyceride (r 0.56, P 0.001), HDL cholesterol (r 7 0.45, P 0.010), VLDL cholesterol (r 0.57, P 0.001), VLDL triglyceride VLDL apoB secretion in men with visceral obesity FM Riches et al (r 0.58, P 0.001), fasting insulin (r 0.54, P 0.001) and fasting glucose (r 0.38, P 0.03).
Percentage fat intake was the only dietary variable associated with the hepatic secretion of VLDL apoB (r 0.36, P 0.042). There were no associations between either the hepatic secretion of VLDL apoB and apoE genotype or the concentrations of free fatty acids, mevalonic acid or lathosterol. FCR was correlated with triglyceride concentration (r 7 0.45, P 0.009) and VLDL apoB pool size (r 7 0.40, P 0.022). In multiple linear regression analysis, the association between the hepatic secretion rate of VLDL apoB and fasting insulin concentration remained signi®cant after adjusting for free fatty acid concentration, mevalonic acid concentration, apoE genotype, age and fat intake (Table 6A) . When either the WHR (Table 6B) or the waist circumference (Table 6C) was added to the model, the association between the hepatic secretion of VLDL apoB and insulin concentration persisted.
Discussion
This stable isotope study shows that the hepatic secretion of VLDL apoB is increased in male subjects with visceral obesity. We also showed that the hepatic secretion of VLDL apoB was directly correlated with both the degree of visceral obesity, as measured by the WHR and insulin resistance, as measured by fasting insulin concentration. These associations remained signi®cant after adjusting for grouping variable. The association between VLDL apoB secretion and fasting insulin concentration was independent of age, apoE genotype, mevalonic acid concentration, free fatty acid concentration and fat intake, factors that may potentially in¯uence the hepatic output of apoB. 12,37±40 . The results are consistent with the hypothesis that visceral obesity plays an important role in determining the rate of hepatic secretion of VLDL apoB and that this association may be more VLDL apoB secretion in men with visceral obesity FM Riches et al closely related to the degree of insulin resistance than the rate of de novo cholesterol synthesis. Our data extend previous reports, since we used a larger sample size, a non-radioactive label and multicompartmental modelling of tracer data. In our previous study, 4 we used monoexponential modelling, a small number of volunteers and did not speci®cally select subjects for having visceral obesity. The majority of previous studies examining VLDL apoB metabolism have used radioactive tracers, exogenously labelling VLDL with 131 I. Kissebah et al 21 demonstrated that in normolipidaemic, moderately obese subjects the hepatic secretion of VLDL apoB (mgakgad) was higher than those of nonobese subjects. A subsequent study by Ginsberg et al 24 demonstrated that in four obese hypertriglyceridaemic males, the hepatic secretion of VLDL apoB was increased (mgakgad). After weight loss, apoB secretion decreased to levels seen in normal weight individuals. Kesaniemi et al 25 found that compared with ®ve normal subjects, four obese subjects (146% of ideal body weight) had increased synthesis rates of VLDL apoB when expressed as mga%ideal body weightad but not when expressed as either mgad or mgakgad. Egusa et al 22 reported that the hepatic secretion of VLDL apoB was signi®cantly increased in obese Pima Indians compared with the lean controls when expressed as mgad or mgakg FFMad, but not when expressed as mgakgad.
In the present study, waist circumference and WHR were used to measure the amount of visceral adipose tissue. Magnetic resonance imaging (MRI) has shown that intra-abdominal fat is strongly correlated with both the waist circumference and the WHR, 41 consistent with our own observations. We examined 41 healthy male subjects and found that visceral adipose tissue area at the L1±L5 vertebrae, as measured by MRI, was highly correlated (P`0.001) with the WHR and waist circumference (Riches FM et al, unpublished observation 1996). Given the limitations of our statistical analysis, our study demonstrates that both the waist circumference and WHR are positively correlated with the hepatic secretion of VLDL apoB. MRI data on the 16 obese subjects suggests that it is the visceral adipose tissue at the L4 vertebrae that best predicts the hepatic secretion of VLDL apoB (data not shown). Although the WHR and waist circumference are important anthropometric predictors of cardiovascular risk, 42 the underlying mechanisms are unclear. Our ®ndings are consistent with the involvement of both insulin resistance 5 and increased hepatic output of apoB. 8 Although it might have been preferable to estimate insulin resistance using a hyperinsulinaemic, euglycaemic clamp, 43 fasting insulin is well correlated with insulin resistance measured by this technique. 44 In the present study, the regulation of VLDL apoB secretion appeared to be closely linked with hyperinsulinaemia. Recent in vitro 14, 15 and in vivo 16, 17 studies have demonstrated that acute hyperinsulinaemia decreases the hepatic secretion of VLDL apoB in the nondiabetic state. By contrast, studies using rat livers VLDL apoB secretion in men with visceral obesity FM Riches et al have shown that in the long-term, insulin stimulates VLDL apoB secretion. 45, 46 This may however, have been due to development of insulin resistance via insulin receptor downregulation. Our ®ndings suggest that in visceral obesity there is increased secretion of VLDL apoB which may in part be due to loss of sensitivity to the normal insulin-mediated suppression of VLDL apoB secretion. It is possible that insulin regulates the hepatic secretion of VLDL apoB by limiting the supply of lipid substrate. 47 Hyperinsulinaemia decreases the delivery of free fatty acids, glycerol or triglycerides to the liver and inhibits hepatic cholesterol synthesis. 17 It is also possible that insulin decreases the hepatic secretion of VLDL apoB via inhibition of apoB translation 48 and increased degradation of apoB in the endoplasmic reticulum. 14 Bjorntorp 42 has suggested that the higher incidence of hyperinsulinaemia in patients with abdominal obesity may be due to the reduced hepatic extraction of insulin from the portal circulation. This may be a result of the higher metabolic activity of visceral adipose tissue causing a greater ux of free fatty acids to the liver. That we did not ®nd a correlation in the present study between plasma free fatty acid concentrations and hepatic secretion of VLDL apoB, may be attributed to differences between peripheral and portal vein free fatty acid concentration. Free fatty acid turnover rate may also be a more important correlate of hepatic apoB output and this requires further examination.
The association between the hepatic secretion of VLDL apoB and plasma triglyceride concentration was expected, since apoB is the main transport protein for endogenously synthesized triglycerides. The metabolic basis for this association may be a consequence of the direct effect of an uptake by the liver of triglyceride-rich VLDL that in turn drives the hepatic secretion of apoB in visceral obesity. 13 Our results suggest that a decreased FCR of VLDL apoB in visceral obesity may also contribute to expansion in the plasma triglyceride pool and indirectly to enhanced apoB secretion. Conversely, both in vitro 11 and in vivo 12 experiments suggest that the intrahepatic pool of cholesterol ester regulates apoB secretion. In visceral obesity it is likely that the availability of both cholesterol and triglycerides are important.
We set out to examine subjects on their usual diets, since we wished to test correlations between hepatic apoB secretion and nutrient intake across a wide and habitual range. We also intended to study apoB secretions while subjects were in a steady state of energy and nutrient consumption. That we achieved this, is supported by our observation that body weight did not vary by more than 3% in the four weeks prior to the commencement of the study. Our data demonstrated a positive correlation between hepatic secretion of VLDL apoB and total fat intake, but the strength of this association was weaker than that between VLDL apoB and plasma insulin concentration. Increased delivery of dietary fat to the liver may contribute to enhanced apoB output by increasing the size of a regulatory pool of neutral lipid. We have not con®rmed a previously reported effect of the polyunsaturated : saturated fat ratio, 49 dietary carbohydrate 40 and the apoE gene polymorphism on VLDL apoB secretion. 38 Genetic polymorphisms not examined in the present study, for example, apoB signal peptide, 50 microsomal transfer protein 51 and the adipsin-acylatin stimulating protein, 10 might have contributed to variation in VLDL apoB secretion. Although we have previously shown a direct correlation between the hepatic secretion of VLDL apoB and plasma mevalonic acid concentration, 12 this association was not observed in the present study. Our present ®ndings suggest that resistance to a direct effect of insulin on the hepatic processing of apoB may play a more important role in regulating the hepatic output of VLDL apoB in obesity than an increase in the rate of de novo cholesterol synthesis. However, we concede that since insulin resistance results in a cluster of metabolic changes, for example increased plasma triglyceride and mevalonic acid concentrations, it is dif®cult in a study of this design to dissociate the independent effects of different lipid substrates on apoB secretion by the liver.
Our study does have limitations. Although we have not examined the kinetics of intermediate-density lipoprotein (IDL) or LDL apoB, we would anticipate that obese subjects would have an increase in the synthesis of these lipoproteins from VLDL. We also did not distinguish VLDL subspecies, but given that the mean triglyceride : apoB ratios were similar in obese and controls, we would infer that the transport of apoB in both large and small VLDL would be higher in obese than control subjects. However, recent studies investigating the regulation of these subfractions have shown that in men with non-insulin dependent diabetes mellitus, insulin is unable to inhibit acutely the release of VLDL 1 despite suppression of free fatty acids. This may contribute to the increased triglyceride levels. 52 Finally, although it may not be strictly considered valid to pool data from two distinct samples for correlational analysis, we attempted to homogenise the groups by making adjustments for variables that distinguished the two populations studied (for example, dietary fat intake, mevalonic acid concentration and WHR). Accordingly, there was a degree of overlap with most of the variables between the non-obese and obese subjects. Furthermore, we acknowledge that although a signi®cant correlation exists between variables it does not imply a cause-effect relationship.
Conclusion
Our data have shown that the hepatic secretion of VLDL apoB is increased in visceral obesity. This may contribute to the elevated lipid concentrations and risk VLDL apoB secretion in men with visceral obesity FM Riches et al of coronary heart disease 8 observed in obese patients and may be a consequence of insulin resistance. Additional studies are warranted to examine the effects of a reduction in visceral adipose tissue and improvements in insulin resistance on the hepatic secretion of VLDL apoB and transport of apoB through the VLDL-IDL-LDL cascade.
